Back to School: How biopharma can reboot drug development. Access exclusive analysis here

rPA reteplase data

Preliminary data from the first 280 patients enrolled in Boehringer's 324-patient RAPID 2 trial showed statistically significant improvement of the German company's drug over GNE's tPA in the numbers of open heart

Read the full 327 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE